This Trial is Conducted in Europe. The Aim of This Trial is to Investigate Pharmacokinetic (the Exposure of the Trial Drug in the Body) and Pharmacodynamic (the Effect of the Investigated Drug on the Body) Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 31 Oct 2017 Planned End Date changed from 14 Oct 2017 to 28 Feb 2018.
- 31 Oct 2017 Planned primary completion date changed from 14 Oct 2017 to 28 Feb 2018.
- 30 Jun 2017 Planned primary completion date changed from 14 Apr 2017 to 14 Oct 2017.